2002
DOI: 10.1078/0065-1281-00662
|View full text |Cite
|
Sign up to set email alerts
|

NADPH-diaphorase activity in the spinal cord after ischemic injury and the effects of pretreatment with Ginkgo biloba extract (EGb 761)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
14
0

Year Published

2006
2006
2009
2009

Publication Types

Select...
6
1

Relationship

4
3

Authors

Journals

citations
Cited by 15 publications
(14 citation statements)
references
References 14 publications
0
14
0
Order By: Relevance
“…In our previous study we described the more resistant nitrergic neurons in the dorsal horns and pericentral area of the spinal cord after ischemia/reperfusion and NADPH-d histochemistry (Mechírová and Domoráková, 2002). Vulnerable neurons in the intermediate zone and ventral horns remained NADPH-d negative.…”
Section: Discussionmentioning
confidence: 95%
“…In our previous study we described the more resistant nitrergic neurons in the dorsal horns and pericentral area of the spinal cord after ischemia/reperfusion and NADPH-d histochemistry (Mechírová and Domoráková, 2002). Vulnerable neurons in the intermediate zone and ventral horns remained NADPH-d negative.…”
Section: Discussionmentioning
confidence: 95%
“…Bilobalide component of EGb 761 increases the respiratory control ratio of mitochondria and protects against the uncoupling of oxidative phosphorylation, by this way increases ATP levels (DeFeudis 2002), influences cognitive deficits that follow stress or traumatic brain injury (DeFeudis and Drieu 2000). Positive effects of EGb 761 pretreatment on neurons after ischemia/reperfusion were confirmed by studies of global ischemia in the rats (Hrehorovska et al 2004;Domorakova et al 2006) or in the gerbils (Chandrasekaran et al 2002) and in the rabbit spinal cord ischemia (Mechirova and Domorakova 2002;Mechirova et al 2006). Less data were found about ischemia/reperfusion and EGb 761 posttreatment.…”
Section: Introductionmentioning
confidence: 83%
“…In patients with mild cognitive impairment neuroprotective drugs according experimental results (Mechirova and Domorakova, 2004) are used. A large problem of clinical practice is late onset of therapy with inhibitors of acetylcholinesterase or memantin, which are the symptomatic and it seems also neuroprotective therapy for patients with AD.…”
Section: Discussionmentioning
confidence: 99%